Toctino (alitretinoin) / Basilea - LARVOL DELTA

Real-World Effectiveness and Safety of Oral Alitretinoin in Chronic Hand Eczema with Exploratory Off-Label Indications: A 10-Year Single-Center Korean Study. (PubMed, Medicina (Kaunas)) - "Lipid elevation was common, supporting routine surveillance. Off-label findings, particularly in PPP and MF, should be interpreted cautiously given small subgroups and non-standardized retrospective assessment."

Journal • Real-world evidence • Retrospective data • Contact Dermatitis • Cutaneous T-cell Lymphoma • Dermatology • Dyslipidemia • Immunology • Metabolic Disorders • Mycosis Fungoides • Oncology • Pain • Psoriasis

Systemic treatments (EADV 2026) - "Alitretinoin remains the systemic benchmark in chronic hand eczema, while dupilumab and emerging targeted therapies are redefining expectations for selected patient groups. 4. Understand how emerging immunological and molecular insights are shaping the next generation of targeted treatment strategies."

Contact Dermatitis • Dermatology • Immunology • SYK

Health-Related Quality of Life and work productivity improvements with topical delgocitinib vs oral alitretinoin in Chronic Hand Eczema: phase 3 DELTA FORCE results (EADV 2026) - No abstract available

Clinical • HEOR • P3 data • Contact Dermatitis • Dermatology • Immunology

Hand eczema and its subtypes (EADV 2026) - "Finally, a stepped-care management approach will be outlined, from prevention and patient education to topical therapy (topical corticosteroids and calcineurin inhibitors), before advancing to therapies for refractory cases (phototherapy, alitretinoin, oral corticosteroids, cyclosporin, azathioprine, methotrexate, acitretin) and the topical pan-JAK inhibitor delgocitinib. Investigative work-up and exposure identification: participants will focus on patient history and diagnostic tools (patch testing, prick testing) to detect relevant triggers. Application of therapeutic algorithm: attendees will master a stepwise treatment protocol, progressing from basic therapy (emollients / skin care, exposure reduction) to topical and systemic therapy, focusing on treatment choice through clinical cases and gaining confidence of using targeted therapies like delgocitinib."

Contact Dermatitis • Dental Disorders • Dermatology • Immunology • Urticaria

Efficacy and safety of Alitretinoin versus Cyclosporine A in patients with moderate-to-severe chronic hand eczema (ALICsA): a randomised, open-label trial with blinded outcome assessment (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Targeted blood-brain barrier penetration for traumatic brain injury therapy via RXR/PPAR-driven microglial M2 polarization. (PubMed, Mater Today Bio) - "We designed a biomimetic nanomedicine (Ali-NPs@Mexo) by encapsulating alitretinoin(Ali)-loaded albumin nanospheres within mesenchymal stromal cell (MSC)-derived exosomal membranes...In vivo, Ali-NPs@Mexo significantly improved functional and cognitive outcomes in mice. This integrated strategy of targeted immune-modulation and neuro-regeneration provides a translatable framework for effective TBI intervention."

Journal • CNS Disorders • Immune Modulation • Immunology • Inflammation • Solid Tumor • Vascular Neurology

Efficacy and Safety of Alitretinoin for Chronic Hand Eczema: A Meta-Analysis. (PubMed, Ann Dermatol) - "Alitretinoin showed favorable efficacy in chronic hand eczema. Consistent with previous studies, we observed a trend of increasing efficacy with higher dosages. Furthermore, at high dosage, greater efficacy was observed with longer durations of use. Adverse events were generally tolerable, supporting its role as a therapeutic option in refractory cases."

Journal • Retrospective data • Back Pain • Dermatology • Dry Eye Disease • Immunology • Musculoskeletal Pain • Pain

A Multi-Center, Open-Label, Single-Arm, Prospective Investigator Initiated Trial to Evaluate the Efficacy and Safety of Alitretinoin in Patients With Chronic Hand Eczema in Real-World Practice (DWALG_P401) and Overview of Korean Studies. (PubMed, Ann Dermatol) - "Oral alitretinoin at daily doses of 10 mg or 30 mg demonstrated effective symptom improvement and an acceptable safety profile in Korean patients with CHE in a real-world setting."

Journal • Real-world evidence • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Pain

Evaluation of delgocitinib for the treatment of moderate to severe chronic hand eczema in adults. (PubMed, Expert Opin Pharmacother) - "Alitretinoin, a vitamin A derivate licensed as a systemic treatment option in Europe, has demonstrated efficacy but is accompanied by systemic adverse effects. Delgocitinib is a topical pan-janus kinase (JAK) inhibitor and represents a novel treatment option for CHE with a favorable safety and tolerability profile. Further data on long-term use and real-world effectiveness are still needed."

Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Inflammation

The Cardiocutaneous Conundrum and the role of multidisciplinary management (BAD 2026) - "She was commenced on alitretinoin for symptomatic keratoderma and referred for restorative dental assessment...Teledermatology Oral presentations BT01 (P207) Evaluation of more than 6000 referrals to dermatology for urgent suspected cancer managed by digitized store-and-forward teledermatology as an alternative to face-to-face assessment Nafisa Miah, Charlotte Michelmore, Shivani Parmar and Bernadette De Silva This abstract is also presented as a Bristol Cup poster, P207, and is available at https://doi.org/10.1093/bjd/ljag086.234. i232 Abstracts"

Cardiomyopathy • Congestive Heart Failure • Heart Failure • Pulmonary Disease

Efficacy of oral alitretinoin for concomitant foot eczema in chronic hand eczema. (PubMed, J Eur Acad Dermatol Venereol) - No abstract available

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Revisiting Palmoplantar Inflammatory Dermatoses (EADV-Sp 2026) - "A retrospective outcomes study compared systemic therapy in refractory CHE, evaluating oral alitretinoin versus cyclosporine using 24-week response and drug survival. PPP similarly aligns with psoriasis-adjacent differentiation abnormalities while retaining distinctive clinicopathological features, whereas pompholyx and typical CHE more closely follow an eczematous differentiation pattern. Integrating IHC signatures with real-world systemic treatment outcomes provides a biologically grounded framework that may improve diagnostic precision and guide individualized systemic treatment selection in palmoplantar disease."

Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Psoriasis

Real-time Experience of Alitretinoin Use in Skin Inflammatory Diseases and Mycosis Fungoides: A Multicenter Retrospective Study (EADV-Sp 2026) - "Conclusions Alitretinoin shows proven efficacy in hand eczema and demonstrates promising therapeutic potential in a variety of inflammatory and lymphoproliferative skin disorders, including mycosis fungoides. While generally well tolerated, careful monitoring of headache and dyslipidemia is recommended during long-term therapy."

Retrospective data • Atopic Dermatitis • Contact Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Dermatopathology • Dyslipidemia • Hematological Malignancies • Immunology • Inflammation • Lichen Planus • Lymphoma • Metabolic Disorders • Mycosis Fungoides • Oncology • Plaque Psoriasis • Psoriasis

Treatment response of inflammatory linear verrucous epidermal nevus (ILVEN) to oral alitretinoin (EADV-Sp 2026) - "Conclusions In contrast to most retinoids, alitretinoin is able to bind all six retinoid receptors, and alitretinoin may exert its effect via synergistic activation of multiple retinoid receptors. We propose alitretinoin as a novel, effective, and well-tolerated therapy for ILVEN, which is resistant to most conventional treatments."

Atopic Dermatitis • Cardiovascular • Contact Dermatitis • Dermatitis • Immunology • Pruritus • Rare Diseases

The Clinical Efficacy and Mechanism of Action of Alitretinoin in the Treatment of Alopecia Areata. (PubMed, Ann Dermatol) - "Alitretinoin appears to be a safe and potentially effective treatment for patients with mild to moderate AA unresponsive to conventional therapies. Its role as a monotherapy or adjunctive option in selected cases warrants further investigation through larger controlled studies."

Journal • Alopecia • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Inflammation • Oncology • Pain • IFNG • IL6 • STAT3 • TNFA

A Retrospective Real-World Comparison of Topical Delgocitinib and Localized Cream Psoralen-Ultraviolet A in Chronic Hand Eczema. (PubMed, Dermatol Ther (Heidelb)) - "Delgocitinib and PUVA provided comparable short-term clinical efficacy in CHE, with a numerically greater DLQI reduction for delgocitinib. Proactive delgocitinib maintenance may help sustain disease control. Subtype-adapted treatment strategies could further optimize outcomes."

Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • CNS Disorders • Contact Dermatitis • Dermatology • Immunology • Pain • Pruritus • Sleep Disorder

Comparison of Systemic and Topical Retinoids and the Association of Inflammatory Bowel Disease in Ichthyosis Patients: A Population-Based Cohort Study (AAD 2026) - "Patients with acquired ichthyosis, congenital ichthyosis , or ichthyosis vulgaris treated with systemic retinoids such as alitretinoin, isotretinoin, etretinate, and acitretin (n=449) were identified using validated ICD-10 codes. A comparator cohort treated with topical retinoids such as adapalene, tazarotene, bexarotene, alitretinoin, and tretinoin (n=449) was established... These findings indicate that the protective association is specific to systemic retinoid therapy and highlights the importance of treatment selection in patients with ichthyosis who have comorbid or potential IBD. Future studies should further explore the role of systemic retinoids as potential disease-modifying agents for IBD and other inflammatory conditions in ichthyosis patients."

Clinical • Atopic Dermatitis • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Vitiligo

A Comparison of the Protective effects of Systemic vs Oral Retinoids on Non Melanoma Skin Cancers in Acne Patients: A Retrospective Cohort Study (AAD 2026) - "Two matched cohorts were created: systemic retinoids (alitretinoin, isotretinoin, etretinate, acitretin; n=34,851) and topical retinoids (adapalene, tazarotene, bexarotene, tretinoin; n=34,851). Patients with known NMSC risk factors (chemical exposures, HPV, or use of BRAF inhibitors, cyclosporine, voriconazole, hydrochlorothiazide) were excluded... The enhanced protective effect of systemic retinoids may reflect their deeper influence on keratinocyte turnover and skin cell regeneration compared to topical formulations. Further studies are warranted to clarify the relative efficacy of individual agents and optimize retinoid prophylaxis in high-risk patients."

Retrospective data • Acne Vulgaris • Basal Cell Carcinoma • Genetic Disorders • Kaposi Sarcoma • Non-melanoma Skin Cancer • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

Current and emerging treatments for pediatric chronic hand eczema: A structured review (AAD 2026) - "Alitretinoin, methotrexate, and cyclosporine are used cautiously off-label. Dupilumab, approved for pediatric atopic dermatitis, has shown promising efficacy and safety in P-CHE trials... Effective P-CHE management requires a multifaceted approach that balances efficacy, safety, patient adherence, and family preference. The literature reflects a critical gap in P-CHE specific data, particularly amongst non-atopic subtypes and in the use of systemic therapies. Existing data is primarily derived from limited subgroup analyses within adult predominant trials, or from patients with atopic hand dermatitis enrolled within larger atopic dermatitis studies."

Clinical • Review • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema. (PubMed, J Drugs Dermatol) - "This consensus provides practical guidance supporting individualized, steroid-sparing CHE management while identifying areas for future research. &nbsp."

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Inflammation • Pain • Pruritus

Vitamins and the Skin: Vitamin A and Retinoids in Dermatology. (PubMed, Clin Dermatol) - "Retinoids used as therapeutic agents include oral retinoids, e.g. isotretinoin, acitretin, alitretinoin, and bexarotene, and topical retinoids, e.g. isotretinoin, tretinoin, adapalene, tazarotene, and trifarotene. In addition, other retinoids, with distinct routes of administration (oral or topical), and distinct dosing or safety profiles, are recommended for different skin disorders. We discuss the mode of action and indications of retinoids used as pharmacologic agents in dermatology and provide an update on their use, effectiveness and tolerability."

Journal • Acne Vulgaris • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Malignancies • Immunology • Lymphoma • Oncology • Psoriasis • Skin Cancer • Squamous Cell Carcinoma • T Cell Non-Hodgkin Lymphoma • Vitiligo

The Patient Journey: From Diagnosis to Therapeutic Management of Chronic Hand Eczema. (PubMed, Dermatitis) - "Topical corticosteroids remain the first-line treatment, whereas phototherapy and systemic options, including alitretinoin and immunosuppressants, are indicated in refractory cases. Recently, novel agents such as topical delgocitinib and biologics like dupilumab have expanded the therapeutic armamentarium, particularly for atopic CHE...Despite these advances, there is still a lack of standardized diagnostic tools, validated severity measures, and evidence-based treatment algorithms. Future efforts should focus on patient-centered, multidisciplinary care and further research to optimize disease control and quality of life in CHE."

Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Single-Cell Regulatory Network Analysis Identifies Adjunctive Drug Candidates in Early Risankizumab-Treated Psoriasis. (PubMed, Curr Pharm Des) - "These findings offer preliminary clues for future risankizumab-based combination strategies in psoriasis."

Journal • Dermatology • Immunology • Infectious Disease • Oncology • Psoriasis • CD4 • ELF3 • KLF5 • KLF9 • KRT14 • KRT6A • MAFB • NFIC • S100A8 • S100A9 • SREBF1

Retinoids enhance NK effector function against HIV-infected CD4 T cells. (PubMed, J Virol) - "From the retinoids tested, alitretinoin, tazarotene acid, and AM80 significantly enhanced NK natural cytotoxicity in the presence of IL-15. This makes the infected cells more vulnerable to being eliminated. Since some of these retinoids are already approved for medical use, they could offer a promising way to reduce persistent HIV reservoirs in the body and improve efforts to cure the infection."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4 • IL15

Hand eczema: comprehensive management and therapeutic perspectives in primary care (PubMed, Semergen) - "A focused history and clinical examination enable diagnostic orientation and allow the initiation, from the first consultation, of appropriate topical treatment, emollient use, and protection against triggering factors. Referral should be considered in severe, refractory cases or those with significant functional or occupational impact, in order to assess advanced therapies such as phototherapy, alitretinoin, dupilumab, oral JAK inhibitors, or topical delgocitinib."

Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus